Skip to Content
Merck
All Photos(1)

Key Documents

S7071

Sigma-Aldrich

SD-208

≥98% (HPLC), powder

Synonym(s):

2-(5-Chloro-2-fluorophenyl)pteridin-4-yl]pyridin-4-yl-amine

Sign Into View Organizational & Contract Pricing

Select a Size

30 MG
€1,030.00

€1,030.00


Estimated to ship onMay 17, 2025


Request a Bulk Order

Select a Size

Change View
30 MG
€1,030.00

About This Item

Empirical Formula (Hill Notation):
C17H10ClFN6
CAS Number:
Molecular Weight:
352.75
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

€1,030.00


Estimated to ship onMay 17, 2025


Request a Bulk Order

Quality Level

Assay

≥98% (HPLC)

form

powder

color

off-white to tan

solubility

DMSO: >5 mg/mL

storage temp.

2-8°C

SMILES string

Fc1ccc(Cl)cc1-c2nc(Nc3ccncc3)c4nccnc4n2

InChI

1S/C17H10ClFN6/c18-10-1-2-13(19)12(9-10)15-24-16-14(21-7-8-22-16)17(25-15)23-11-3-5-20-6-4-11/h1-9H,(H,20,22,23,24,25)

InChI key

BERLXWPRSBJFHO-UHFFFAOYSA-N

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
1598338PHR31281598347
manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

-

format

neat

API family

ramipril

API family

ramipril

API family

-

API family

ramipril

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

Application

SD-208 was used to inhibit the activity of ALK5 kinase in bovine retinal vascular cells.2

Biochem/physiol Actions

SD-208 is TGF-βR I kinase inhibitor with IC50 =49 nM based on direct enzymatic assay of TGFRI kinase (ALK5) activity with a specificity of >100-fold against TGFRII and at least 17-fold over members of a panel of related protein kinases including p38a, p38b, p38d, JNK1, EGFR, MAPKAPK2, MKK6, ERK2, PKC, PKA, PKD, CDC2, and CaMKII.
SD-208 is a novel transforming growth factor beta receptor I (TGF-βR I) kinase inhibitor. SD-208 inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
SD-208 is an inhibitor of TGF β receptor 1 kinase that is reportedly effective against human malignant gliomas. It increases the lytic activity and tumor infiltration by polyclonal natural killer cells, CD8 T cells and macrophages.1

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

  • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Katharina Seystahl et al.
    Neuro-oncology, 17(2), 254-265 (2014-08-29)
    The transforming growth factor (TGF)-β and vascular endothelial growth factor (VEGF) pathways have a major role in the pathogenesis of glioblastoma, notably immunosuppression, migration, and angiogenesis, but their interactions have remained poorly understood. We characterized TGF-β pathway activity in 9
    Tanja Stüber et al.
    Journal for immunotherapy of cancer, 8(1) (2020-04-19)
    Immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells is effective in some hematologic tumors. In solid tumors, however, sustained antitumor responses after CAR T-cell therapy remain to be demonstrated both in the pre-clinical and clinical setting. A perceived barrier to the
    Martin Uhl et al.
    Cancer research, 64(21), 7954-7961 (2004-11-03)
    The cytokine transforming growth factor (TGF)-beta, by virtue of its immunosuppressive and promigratory properties, has become a major target for the experimental treatment of human malignant gliomas. Here we characterize the effects of a novel TGF-beta receptor (TGF-betaR) I kinase
    Chandan K Nagaraju et al.
    Scientific reports, 9(1), 8879-8879 (2019-06-22)
    After myocardial infarction, resident fibroblasts (Fb) differentiate towards myofibroblasts (MyoFb), generating the scar tissue and the interstitial fibrosis seen in the adjacent myocardium. Fb and MyoFb have the potential to interact with cardiac myocytes (CMs) but insight into the phenotype-specific
    Elisa Ventura et al.
    Journal of immunology (Baltimore, Md. : 1950), 198(12), 4569-4574 (2017-05-10)
    Glioblastoma is the most common and aggressive intrinsic brain tumor in adults. Self-renewing, highly tumorigenic glioma-initiating cells (GIC) have been linked to glioma invasive properties, immunomodulation, and increased angiogenesis, leading to resistance to therapy. TGF-β signaling has been associated with

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service